Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

f-of-concept trial noted outlined above. With the positive initial results from that clinical trial and the decision to move forward to a Phase 2b outpatient clinical trial in migraine patients, Alexza must file a new IND with the DNP. It is projected that the Company will file this new IND in the fourth quarter of 2008 and initiate our Phase 2b outpatient study in the first quarter of 2009. AZ-104 has been licensed to Symphony Allegro, and Alexza has the right to repurchase all rights to this product candidate.

-- AZ-002 (Staccato alprazolam). Alexza is developing AZ-002 for the acute treatment of panic attacks associated with panic disorder. In June 2008, the Company announced the top line results of our in-clinic, single-center, double-blind, placebo-controlled, Phase 2a proof-of-concept clinical trial in patients with panic disorder. The primary aim of the clinical trial was to assess the safety and efficacy of a 1 mg single dose of AZ-002 in treating a pharmacologically-induced panic attack. Differences versus placebo in the intensity and the duration of a panic attack were collected at multiple time points during the study using psychological and physiological measurements. The study did not meet its two primary endpoints, which were the effect of AZ-002 on the incidence of a doxapram-induced panic attack and the effect of AZ-002 on the duration of a doxapram-induced panic attack, both as compared with placebo. There were no serious adverse events in the clinical trial, and AZ-002 was safe and well tolerated in the study patient population.

Thorough pharmacokinetic and pharmacodynamic analyses from this study show that alprazolam was administered in an IV-like manner with the Staccato system. Similar blood levels were observed in this study as were recorded during the AZ-002 Phase 1 PK and safety study in normal volunteers. Alexza and Symphony Allegro are completing work on the Phase 2a program for AZ-002 in acute panic attack. Following this com
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Ala. , Aug. 27, 2015 /PRNewswire/ ... Outpatient Pharmacy Provider (IOPP™) is expanding its ... of a medication-focused transition of care program ... named "RxCare Management," provides hospitals with technology ... hospital performance measures that have been mandated ...
(Date:8/27/2015)... , Aug. 27, 2015  A mere one ... Booz Allen Hamilton . A new white ... development inefficiencies are impeding and disrupting manufacturers, success. ... Waste and Improve Value In Product Development Processes ... inaccessible data and how it affects the product development ...
(Date:8/27/2015)... NorthStar Anesthesia , one of the country,s ... selected by Mercy, based in Toledo, Ohio ... hospitals:  Mercy St. Vincent  Medical Center and Mercy St. ... St. Charles  Hospital in Oregon and ... "As we looked to create a more ...
Breaking Medicine Technology:Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2
... CYBX ), a global leader in epilepsy management, today ... Sciences Conference on Wednesday, September 21, 2011, in New York. ... will speak to the attendees of the conference 10:00 AM ... be accessed by clicking on the Investor Relations link on ...
... 7, 2011 Generex Biotechnology Corporation ( www.generex.com ... the Company,s President & Chief Executive Officer, and ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ) ... & Renshaw 13th Annual Healthcare Conference.  The presentation ...
Cached Medicine Technology:Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 3
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to ... a cutting-edge, noninvasive procedure to improve submental fat. The first and only Food ... without surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, making ... Insurance is sharing some tips to help your whole family travel safely and comfortably. ... with pets each year. Amica is sharing the following tips from the American Society ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... Analysis signed a partnership agreement for quality market research promotion on the ... by Black Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its ... grown to having twelve offices in three counties, LA, Orange and San Bernardino. ... California region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope ...
Breaking Medicine News(10 mins):Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
... patients with the help of seroquel is effective//, ... chronic severe disabling mental illness. Some of the ... heard, feelings of being persecuted, becoming withdrawn, and ... only one in five patients have a chance ...
... diabetes drug thiazolidinediones (TZDs) can cause //edema. ,Scientists from ... activates a receptor in kidney called peroxisome proliferator-activated receptor gamma ... kidney. The activation of the receptor serves to retain the ... are generally used to lower blood sugar levels and lipid ...
... increase the risk of the Alzheimer’s disease// if people ... to a research study that is presented in the ... held in US, periodontal conditions could affect the incidence ... the brain cells and slowly destroys them. The main ...
... friendship that can keep people have a long life//. ... of having friends do affect the health and emotional well ... get significantly increased. ,The researchers had surveyed about ... the phone for about ten years in the age group ...
... had licensed the use of strontium ranelate to be used ... prescribing the drug it is important to observe the changes ... British Medical Journal has said that the drug strontium ranelate ... that this effect can be used in advantage of the ...
... have shown that consumption of trans fatty acids ... disease. Trans fatty acids are the hydrogenated and ... baked goods and many processed foods. They are ... in the presence of metal catalysts and in ...
Cached Medicine News:
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... can operate in two additional modes. The ... creating a fully featured handheld pulse oximeter, ... used to upgrade existing equipment through the ... or software upgrades to improve the performance ...
... The stylish Avant® 9600s simple functionality, ... of memory makes it well-suited for ... proven digital pulse oximetry, the Avant ... rugged durability. The 9600 provides a ...
Medicine Products: